Molplex Information

Molplex is a drug discovery company building portfolios of pre-clinical drug candidates for licensing. Molplex uses Artificial Intelligence (AI), Big Data and automated laboratory systems to rapidly identify new drug candidates at a fraction of the normal cost, de-risk discovery across a broad portfolios of drug assets. We acquire shelved assets as data packages from pharma and innovative universities in return for a share of future returns. Our systems rapidly sift through opportunities to search out the most promising compounds and the most commercially promising projects so we can focus laboratory work on the very best, driving down the costs of failure. While the average industry cost of inventing a new clinic-ready drug is £15M, we think we can do this for less than £1M Our A.I. discovery engine is fully operational and we have an active and expanding discovery portfolio of 6 new medicines in oncology, infection and dermatology with reference markets in excess of £1bn.